Exciting news! Precision oncology company Flindr Therapeutics (formerly known as Immagene), a spinoff from Oncode Institute and the Netherlands Cancer Institute (NKI), has raised €20 million in its recent Series A investment round. This will allow the company to accelerate development of its first-in-class lead programme and to broaden its pipeline using its ImmunoGram discovery engine. A warm welcome goes out to the new investor syndicate, led by V-Bio Ventures and supported by co-investments from Johnson & Johnson Innovation – JJDC, Inc. (JJDC), QBIC Fund, Flanders Future Tech Fund (PMV), Oncode Oncology Bridge Fund, Swanbridge and Curie Capital.
We are incredibly proud of Flindr Therapeutics. We have supported the company from its inception, all the way to its Series A round through Oncode Oncology Bridge Fund. This is not only a major milestone for the company but it also affirms Oncode Institute’s commitment to translating pioneering research into therapies for cancer patients. The current support of an international investor syndicate is also a great recognition of the exceptional quality of the research of Flindr's scientific founders - Oncode Investigator Daniel Peeper, NKI oncologist Christian Blank and founding CEO Maarten Ligtenberg.
Congratulations to the entire Flindr team for their dedication and hard work, resulting in this important achievement.
You can read the full press release about this here.